 Patients whose disease returns during the first course of vaccine therapy will have surgery to remove the tumor and will continue to receive the vaccine treatment. Patients whose tumor returns after completing one course of therapy may receive a substance called interleukin-2 IL-2, which can boost immune function against the tumor. interleukin-2 IL-2 is given intravenously through a small tube placed in a vein every 8 hours for 4 days. This regimen is repeated after 10 to 14 days. Those who respond to interleukin-2 IL-2 will have a third course of treatment after 2 months. Patients whose disease recurs after treatment will be taken off the study and will be referred back to their referring physician or to another study, if an appropriate one is available. 